The Cannabis Use Disorder (CUD) market is witnessing accelerated growth propelled by rising awareness of cannabis addiction and the demand for effective treatment options. With increasing prevalence globally, the market developments reflect a surge in research, innovative therapeutics, and supportive regulatory environments shaping the future business growth and industry size.
Market Size and Overview
- The Global Cannabis Use Disorder Market size is estimated to be valued at USD 1.80 billion in 2025 and is expected to reach USD 3.40 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.
- The increasing Cannabis Use Disorder Market Size of cannabis use disorders combined with advances in pharmacological and behavioral therapies highlight the expanding market scope.
- Recent market insights illustrate that growing investments in R&D and regulatory approvals for treatment options are driving positive market revenue and market growth dynamics.
Market Drivers
- The key market driver is the rising prevalence of cannabis use globally, with healthcare organizations reporting increased cases of cannabis dependency in 2024 and 2025. For example, the National Institute on Drug Abuse cited a 15% rise in cannabis use disorder diagnoses in 2024 within the U.S., directly fueling demand for effective treatment solutions.
- The evolution of precision medicine and novel therapeutics from companies such as Pfizer and Zynerba Pharmaceuticals further accelerates the market growth by providing innovative and targeted treatment options.
- These market dynamics open significant market opportunities for new drug development and advanced therapies.
PEST Analysis
- Political: Governmental support in key regions, including increased funding for addiction treatment programs in North America and Europe, influences market growth positively. In 2025, new policies aimed at regulating cannabis use disorder treatment reimbursement emerged, expanding market revenue.
- Economic: The rising disposable income and healthcare expenditure globally, especially in developed countries, enhance accessibility to cannabis use disorder treatment medications and services, supporting market expansion.
- Social: Growing social awareness about cannabis addiction and its implications has led to increased patient willingness to seek treatment, evidenced by a 2024 survey indicating a 20% increase in treatment-seeking behavior in Europe.
- Technological: Advancements in drug delivery systems and development of novel cannabinoid receptor antagonists by companies like Corbus Pharmaceuticals exemplify technological improvements fostering market growth strategies. Such innovations improve treatment efficacy and patient compliance.
Promotion and Marketing Initiative
- Recent marketing initiatives focus on educational campaigns and stakeholder collaborations to boost treatment adoption. For instance, in 2024, Indivior launched a global awareness campaign through digital platforms targeting healthcare professionals, which enhanced therapy prescriptions by 18% within six months post-launch.
- These promotional activities not only improve market size and revenue but also create a constructive impact on patient engagement and market penetration in emerging economies.
Key Players
- Prominent market players include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, Zynerba Pharmaceuticals, among others.
- In 2025, Pfizer expanded its portfolio by launching an innovative cannabinoid-based therapy targeting CUD, eliciting favorable market response and increasing their industry share.
- Zynerba Pharmaceuticals secured strategic partnerships in 2024 for clinical trials enhancing its product pipeline and reinforcing competitive positioning.
- Aelis Farma invested heavily in R&D to accelerate new drug approvals, thus augmenting their market share and boosting market revenue.
- Corbus Pharmaceuticals focused on expanding geographic reach in 2025, entering key Asian markets and leveraging market opportunities due to increasing cannabis use disorders in the region.
- Indivior’s recent acquisition of a biotech startup specializing in behavioral therapies contributed to a diversified product lineup and increased market presence globally.
FAQs
Q1. Who are the dominant players in the Cannabis Use Disorder market?
A1. The dominant companies shaping the Cannabis Use Disorder market include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals. These market players are driving growth through continuous product innovation, clinical trials, and strategic partnerships.
Q2. What will be the size of the Cannabis Use Disorder market in the coming years?
A2. The Cannabis Use Disorder market size is projected to grow from USD 1.80 billion in 2025 to approximately USD 3.40 billion by 2032, reflecting a significant CAGR of 9.5% driven by increased treatment demand worldwide.
Q3. Which end-user industry segment holds the largest growth opportunity?
A3. The healthcare sector, particularly specialized addiction treatment centers and hospitals, presents the largest growth opportunity due to increasing patient inflow and expanding insurance coverage for cannabis dependency treatments.
Q4. How will market development trends evolve over the next five years?
A4. Market trends indicate stronger adoption of personalized medicine, integration of digital therapy platforms, and development of novel synthetic cannabinoid antagonists, which collectively will shape the market’s future growth trajectory through enhanced efficacy and broader accessibility.
Q5. What is the nature of the competitive landscape and challenges in the Cannabis Use Disorder market?
A5. The competitive landscape is moderately concentrated with leading pharmaceutical companies focusing on product differentiation and clinical advancement. Market challenges include regulatory complexities and the need for increased awareness, which strategic marketing initiatives aim to address.
Q6. What go-to-market strategies are commonly adopted in the Cannabis Use Disorder market?
A6. Predominant go-to-market strategies involve collaborative partnerships for clinical development, targeted awareness campaigns for healthcare providers, and expansion into untapped geographic markets, all contributing positively to market revenue and business growth.
Get more insights on : Cannabis Use Disorder Market Size
Get this Report in Japanese Language: 大麻使用障害市場
Get this Report in Korean Language: 대마사용장애시장
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
